Could Arcutis Biotherapeutics unlock the next big pediatric dermatology gap with Zoryve?
Arcutis Biotherapeutics has secured U.S. Food and Drug Administration acceptance of its supplemental New Drug Application for Zoryve roflumilast cream 0.05 percent to expand treatment of mild to moderate atopic dermatitis to infants aged 3 to 24 months. The filing moves the steroid-free topical therapy into a regulatory review with a target action date of
